Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | PAM | P19021 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL22031604 | 0.98 | DGKA (0.71) | DGKANAAAPRSS1PRSS2PRSS3 | |
| Sulfuric Acid SCHEMBL9841068 | 0.96 | DGKA (0.74) | DGKANAAAPRSS1PRSS2PRSS3 | |
| Sulfuric Acid SCHEMBL11347430 | 0.96 | DGKA (0.74) | DGKANAAAPRSS1PRSS2PRSS3 | |
| Sulfuric Acid SCHEMBL27524211 | 0.95 | DGKA (0.71) | DGKANAAAPRSS1PRSS2PRSS3 | |
| Sulfuric Acid SCHEMBL1828752 | 0.93 | HTR2C (0.64) | DGKANAAAPRSS1PRSS2PRSS3 | |
| Sulfuric Acid SCHEMBL11784716 | 0.93 | DGKA (0.74) | DGKANAAAPRSS1PRSS2PRSS3 | |
| Sulfuric Acid SCHEMBL8494850 | 0.91 | NAAA (0.60) | DGKANAAAPRSS1PRSS2PRSS3 | |
| Sulfuric Acid SCHEMBL11047305 | 0.91 | HTR2C (0.66) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL19810537 | 0.91 | DGKA (0.83) | DGKANAAAPRSS1PRSS2PRSS3 | |
| SCHEMBL2171325 | 0.91 | DGKA (0.83) | DGKANAAAPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114796191-A | Application of ER-alpha 36/EGFR signal loop as target in preparation of antitumor drugs | 杭州发通赛医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-108236622-B | Application of composition for down-regulating ER-alpha 36 expression in preparation of medicine for treating triple negative breast cancer | 杭州发通赛医药科技有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-109381515-A | It is a kind of to interfere or block the substance of ER- α 36/EGFR hoop in the application prepared in the drug for treating disease | 杭州发通赛医药科技有限公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-101132779-B | Pharmaceutical compositions comprising omega-carboxyaryl substituted diphenyl ureas for the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2016-03-16 | — | — | CN | disclosed |
| US-20150037399-A1 | NOVEL USE OF PIPOXOLAN AND ITS PHARMACEUTICAL COMPOSITION | CHINA MEDICAL UNIVERSITY (TW) | 2015-02-05 | — | — | US | disclosed |
| CN-101243089-B | Halopyrazolo [1,5-A ] pyrimidines, methods, uses as GABA-A receptor ligands, compositions and intermediate compounds | FERRER INT | 2011-07-06 | — | — | CN | disclosed |
| CN-101243089-A | 3 Halopyrazolo 3 [ 3 1 3, 3 5 3- 3 A 3 ] 3 pyrimidines 3, 3 methods 3, 3 uses 3 as 3 GABA 3- 3 A 3 receptor 3 ligands 3, 3 compositions 3 and 3 intermediate 3 compounds 3 | FERRER INT (ES) | 2008-08-13 | — | — | CN | disclosed |
| CN-101132779-A | Pharmaceutical compositions comprising omega-carboxyaryl substituted diphenyl ureas for the treatment of cancer | BAYER HEALTHCARE AG (DE) | 2008-02-27 | — | — | CN | disclosed |
| US-20010014683-A1 | Analgesics; side effect reduction | ITO FUMITAKA (JP) | 2001-08-16 | — | — | US | disclosed |
| CN-1244532-A | 3,6-aldehyde acetal and enol ether large ring lactone vitamine | PFIZER PRODUCTS CO (US) | 2000-02-16 | — | — | CN | disclosed |
| CN-1046515-C | Diazabicyclic neurokinin antagonists | PFIZER (US) | 1999-11-17 | — | — | CN | disclosed |
| CN-1149870-A | Substituted pyrazoles with corticotropin releasing factor antagonist activity | PFIZER (US) | 1997-05-14 | — | — | CN | disclosed |
| CN-1139434-A | Diazabicyclic neurokinin antagonists | PFIZER (US) | 1997-01-01 | — | — | CN | disclosed |
| US-4359462-A | Antibiotic 67-121, a new polyene antifungal antibiotic produced by Actinoplanes caeruleus | SCHERING CORPORATION (US) | 1982-11-16 | — | — | US | disclosed |
| US-4223130-A | Antibiotic 67-121, a polyene antifungal antibiotic produced by Actinoplanes caeruleus | SCHERING CORPORATION (US) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014683-A1 | Analgesics; side effect reduction | OPRL1, OPRK1, OPRD1 | DGKA 3371/4885NAAA 1474/4885PRSS1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.